title: Recombinant hirudin--initial observations in reconstructive microsurgery.
abstract: Recent advances in microvascular techniques have significantly enhanced the success rate of these procedures. Microvascular free tissue transfers at present have a 85-90% success rate. This, however, still leaves a 10-15% failure rate due primarily to thrombosis of the blood vessels at the anastomotic site. Previous work in the field has shown that anticoagulants such as heparin can reduce the rate of thrombosis. However, heparin can also cause on-site bleeding. Hirudin, a potent thrombin inhibitor of 65 amino acids, is available through recombinant technology. Our current experimental work utilized 75 male Sprague-Dawley rats for assessing the efficacy of hirudinized saline versus saline alone and heparinized saline as an irrigant in a microsurgery model of anastomosis. After exposing the right femoral artery in a standard fashion, the artery was clamped and a standard transverse division of the vessel was made. The vessel ends were irrigated with one of the three solutions then anastomosed. Vessels were observed for patency over a 3-day period. Initial results showed comparable performance of hirudinized saline and heparized saline, both of which were better than saline, for preventing thrombosis. From these initial data, and the reduced bleeding risk associated with hirudin, this agent appears to be a useful anticoagulant in microsurgery.
authors.affiliation: Montefiore Hospital, Division of Plastic Surgery, Pittsburgh, Pa.
authors.forename: K
authors.initials: K
authors.lastname: Narayanan
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
authors.forename: M D
authors.initials: MD
authors.lastname: Liang
authors.forename: J
authors.initials: J
authors.lastname: Fareed
mesh_terms: D000714:Anastomosis, Surgical / Q000009:adverse effects*; D000818:Animals; D005263:Femoral Artery / Q000601:surgery; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D024764:Hirudin Therapy; D008297:Male; D008866:Microsurgery / Q000009:adverse effects*; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000627:therapeutic use; D007507:Therapeutic Irrigation; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins